AstraZeneca exceeds estimates and ups guidance

12 November 2024

Anglo-Swedish drugmaker AstraZeneca (LSE: AZN) beat analyst expectations with its third-quarter 2024 revenue and earnings figures.

The Cambridge-based firm reported revenue of $12.95 billion for the quarter, up 18% on the same period of 2023, and core earnings per share (EPS) of $2.08, up 20%.

AstraZeneca now expects high-teens percentage growth in 2024 revenue and core earnings per share, from a previous forecast of mid-teens percentage growth at constant currency rates.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK